Does Aetna (CVS Health) Cover Trulicity (Dulaglutide)?

What Is Trulicity and Why Does Coverage Matter?

Trulicity is a brand-name, once-weekly injectable GLP-1 receptor agonist approved by the FDA in October 2014 for glycemic control in adults with type 2 diabetes [1]. The FDA expanded its label in 2020 to include cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [2]. At a wholesale acquisition cost of roughly $931 per month, out-of-pocket spending without insurance can equal nearly $11,172 per year, making insurance coverage decisions financially decisive for most patients [3].

The REWIND trial (N=9,901) published in The Lancet in 2019 demonstrated that dulaglutide 1.5 mg weekly reduced the composite of major adverse cardiovascular events (MACE) by 12% relative to placebo over a median 5.4-year follow-up (hazard ratio 0.88 to 95% CI 0.79, 0.99, P=0.026) [4]. That cardiovascular outcome data strengthened insurer rationale for covering the drug, though it did not eliminate the prior authorization gatekeeping that Aetna applies to nearly all branded GLP-1 agents.

The American Diabetes Association's 2024 Standards of Care classify GLP-1 receptor agonists as preferred add-on therapy after metformin for patients with established cardiovascular disease, high cardiovascular risk, chronic kidney disease, or obesity-driven hyperglycemia [5]. Aetna's own clinical policy bulletins track closely with these guidelines but add procedural requirements that physicians and patients must satisfy before a claim is approved [6].

Which Aetna Plans Cover Trulicity?

Most Aetna commercial plans cover dulaglutide, but the specific tier and cost-sharing vary by plan type.

Aetna operates multiple distinct formulary structures depending on whether a member has an employer-sponsored commercial PPO, commercial HMO, Aetna Medicare Advantage, or an ACA Marketplace plan. Trulicity sits on most commercial formularies as a Tier 3 (non-preferred brand) drug [7]. Tier 3 placement means the member cost-share is typically a mid-to-high copay or coinsurance, often $75, $120 per fill on standard commercial plans before deductible is met [8].

Aetna Medicare Advantage plans follow CMS Part D formulary rules. Under Part D, dulaglutide is covered for type 2 diabetes but not for weight loss as a stand-alone indication, consistent with the CMS exclusion of weight-loss drugs from standard Part D benefit [9]. Some Aetna Medicare Advantage plans offer enhanced supplemental drug coverage that may shift this, so members should verify their specific plan's Evidence of Coverage document directly.

ACA Marketplace (individual/family) plans administered by Aetna through CVS Health may place Trulicity on Tier 3 or Tier 4 depending on the specific metal-level plan and state formulary. Checking the Summary of Benefits and Coverage (SBC) or using the Aetna formulary lookup tool at aetna.com before prescribing is the fastest way to confirm tier placement for a specific member.

Aetna's clinical policy bulletin CP.PMN.94 governs GLP-1 receptor agonist coverage across commercial lines and is updated at least annually [6]. Physicians prescribing dulaglutide should review the current version of that bulletin because criteria can shift between plan years.

Prior Authorization Criteria for Trulicity on Aetna

Aetna requires prior authorization for Trulicity on virtually all plan types, and the criteria are moderately strict.

A standard Aetna PA submission for dulaglutide must document all of the following [6] [10]:

Confirmed diagnosis. The member must have a documented diagnosis of type 2 diabetes mellitus, confirmed by ICD-10 code E11.x. Type 1 diabetes does not qualify under the standard diabetes PA pathway.

Inadequate response to or contraindication to metformin. Aetna typically requires that the member has tried metformin at an adequate dose (usually 1,000, 2 to 000 mg/day) for at least 90 days and either failed to reach goal A1C or experienced documented intolerance (e.g., GI toxicity, lactic acidosis risk due to renal impairment) [10].

Step therapy through a sulfonylurea or SGLT-2 inhibitor. Beyond metformin, most Aetna commercial plans require a trial of at least one preferred Tier 2 agent, commonly a generic sulfonylurea such as glipizide or a preferred SGLT-2 inhibitor such as generic dapagliflozin where available, before authorizing a GLP-1 agonist [10]. The required duration of that second agent is typically 60 to 90 days unless intolerance or contraindication is documented.

Prescriber attestation. The submitting physician must attest that the requested drug is medically necessary given the patient's clinical profile, including A1C level, weight, renal function (eGFR), and any concurrent cardiovascular or heart-failure diagnoses [6].

Cardiovascular indication shortcut. If the patient has established atherosclerotic cardiovascular disease (ASCVD) or high 10-year ASCVD risk, Aetna's policy may waive the step-therapy requirement in alignment with ADA 2024 Standards of Care [5] [6]. Documenting ASCVD diagnosis codes (I25.10, I21.x, etc.) in the PA request can reduce the required prior medication trials to metformin alone.

Once submitted, Aetna's standard PA turnaround is 3 business days for non-urgent requests and 72 hours for urgent requests under URAC and NCQA standards [11].

Step Therapy: What Medications Must Be Tried First?

Aetna's step-therapy requirement for Trulicity generally follows a two-step ladder before a GLP-1 agonist is authorized.

Step 1 is metformin. The FDA lists metformin as the preferred first-line pharmacologic agent for type 2 diabetes, and the ADA 2024 Standards of Care reinforce that recommendation [5] [12]. Aetna's policy mirrors this by requiring documented metformin use unless the member has an eGFR <30 mL/min/1.73m², active hepatic disease, alcohol use disorder, or documented GI intolerance.

Step 2 is a preferred oral or injectable agent. Aetna's preferred Tier 2 agents commonly include generic glipizide, glimepiride, pioglitazone, and, on plans updated to reflect the 2023 generic availability, dapagliflozin tablets [10]. Some Aetna plans also accept a Tier 2 DPP-4 inhibitor such as generic sitagliptin as a qualifying second agent.

The step-therapy requirement can be bypassed for documented clinical reasons. Sulfonylureas carry a hypoglycemia risk that may be unacceptable in patients who drive commercially, operate heavy machinery, or have frequent hypoglycemia at baseline. SGLT-2 inhibitors are contraindicated when eGFR <45 mL/min/1.73m² for some indications [13]. Documenting these contraindications in the PA submission, rather than simply requesting a bypass verbally, is the most effective way to avoid step therapy.

The ADA position statement on GLP-1 receptor agonist access, published in Diabetes Care in 2023, explicitly states: "Step therapy protocols that require patients with established cardiovascular disease or chronic kidney disease to fail additional medications before accessing proven GLP-1 receptor agonists may expose patients to unnecessary clinical risk" [14]. This statement gives physicians a guideline-backed argument when requesting step-therapy waivers.

How to Submit a Prior Authorization Request to Aetna

A complete PA packet submitted the first time reduces denial rates significantly.

Prescribers should use Aetna's electronic PA portal (Availity or NaviNet) or fax the Aetna pharmacy prior authorization form specific to the member's plan. The packet should include:

1. The PA request form with ICD-10 and NDC codes for dulaglutide (NDC 00002-1433-80 for the 0.75 mg/0.5 mL pen or 00002-1434-80 for the 1.5 mg/0.5 mL pen).
2. The most recent A1C result with the date drawn.
3. Documentation of metformin trial: start date, highest dose tolerated, and reason for discontinuation or continued use.
4. Documentation of second-agent trial (dates, doses, outcome) or a written statement of contraindication.
5. Most recent eGFR/creatinine and any active cardiovascular diagnoses.
6. A letter of medical necessity from the prescriber, specifically citing the ADA 2024 Standards of Care and, where applicable, the REWIND trial cardiovascular outcome data [4] [5].

The FDA label for Trulicity specifies that the drug is indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and separately "to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors" [2]. Quoting the exact FDA-approved indication in the letter of medical necessity ties the request directly to labeled use, which strengthens the submission.

What to Do If Aetna Denies Trulicity Coverage

Denial is not the end of the road. Aetna has a structured multi-step appeal process.

Step 1: Internal level-1 appeal. File within 180 days of the denial notice. The appeal must include new clinical information not submitted with the original PA, such as a specialist letter, a peer-reviewed reference to REWIND outcomes data [4], or documentation that step-therapy agents caused adverse effects. Aetna is required by federal law (ERISA for employer plans, ACA for individual/marketplace plans) to issue a decision within 30 days for pre-service appeals [15].

Step 2: Internal level-2 appeal or expedited review. If the level-1 appeal is denied, members may request a second internal review. For urgent clinical situations, ERISA mandates an expedited turnaround of 72 hours [15].

Step 3: External independent review. If internal appeals are exhausted and the denial stands, members enrolled in ERISA-governed plans have the right to an Independent Review Organization (IRO) review under the ACA's external review provision [15]. IRO decisions are binding on the insurer for fully insured plans in most states. The IRO must issue a decision within 45 days for standard external reviews.

Step 4: State insurance commissioner complaint. For fully insured state-regulated plans, filing a complaint with the state insurance commissioner can trigger a separate review. State departments of insurance track appeal overturn rates and may flag insurers with high denial rates for audit.

A 2019 analysis in JAMA Internal Medicine found that patients who appealed insurance denials had those denials overturned roughly 39 to 59% of the time depending on plan type and state, underscoring that appeal is worth pursuing [16].

Aetna Coverage of Trulicity for Weight Loss

Aetna does not currently cover dulaglutide specifically for weight loss as a stand-alone indication.

Dulaglutide does not hold an FDA indication for chronic weight management. That indication belongs to semaglutide 2.4 mg (Wegovy), which was approved by the FDA in June 2021 for adults with BMI >30 kg/m² or BMI >27 kg/m² with at least one weight-related comorbidity [17]. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body-weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo (P<0.001) [18].

Some patients with type 2 diabetes experience clinically meaningful weight loss on dulaglutide. The AWARD-11 trial (N=1,842) showed mean weight loss of 4.7 kg with dulaglutide 3.0 mg and 4.5 kg with dulaglutide 4.5 mg versus 2.7 kg with dulaglutide 1.5 mg at 36 weeks [19]. Weight loss is an expected pharmacologic benefit, not the approved indication, and Aetna's PA criteria for dulaglutide require a type 2 diabetes diagnosis.

Prescribing dulaglutide off-label solely for weight loss and submitting a PA under a diabetes ICD-10 code when the patient does not have type 2 diabetes constitutes fraudulent billing and should not be attempted.

Manufacturer Savings Card and Other Cost Reduction Options

The Eli Lilly savings card can dramatically lower out-of-pocket cost for eligible patients.

Eli Lilly offers the Lilly Cares savings program and the Trulicity Savings Card for commercially insured patients. Eligible patients with commercial insurance (not Medicare, Medicaid, or any government-funded plan) may pay as little as $25, $35 per month for Trulicity through the savings card [20]. The savings card bridges the gap between insurance copay and drug cost.

Patients on Medicare Part D cannot legally use the manufacturer savings card under anti-kickback statute provisions. However, they may qualify for the Lilly Insulin Value Program or the Lilly Cares Foundation patient assistance program, which provides the drug at no cost to qualifying low-income patients [20].

For patients whose PA is denied and who are uninsured or underinsured, GoodRx and similar discount programs can reduce the cash price of Trulicity from $931 to approximately $700, $800 per month at select pharmacies, which still represents a substantial cost. Generic dulaglutide is not yet available in the United States as of the article's review date.

The ADA's 2024 Standards of Care state: "Affordability and access to medications are essential components of diabetes management and should be addressed proactively in clinical encounters" [5]. Prescribers should document cost barrier discussions in the medical record, both for quality-of-care purposes and because documented cost barriers can sometimes support a PA appeal on grounds of medical necessity for the least costly effective agent.

How Aetna's Coverage Policy Compares to Other Major Insurers

Aetna's approach to Trulicity is moderately restrictive compared to the broader commercial insurance market.

UnitedHealthcare and Cigna apply similar step-therapy requirements but place different GLP-1 agents as preferred within the class. For example, UnitedHealthcare's commercial formulary as of 2024 often prefers once-weekly semaglutide (Ozempic) over dulaglutide for new starts, meaning a member requesting Trulicity may face a within-class step through Ozempic first [21]. Cigna's formulary structures vary by employer contract but commonly require a trial of liraglutide 1.2 mg (Victoza) or semaglutide 0.5 mg (Ozempic) before authorizing higher-cost GLP-1 formulations [21].

BCBS plans show the most formulary variation because each regional BCBS affiliate maintains its own formulary. Some BCBS affiliates list Trulicity as a Tier 2 preferred brand, which lowers cost-sharing and reduces PA complexity.

Medicaid coverage of dulaglutide varies by state. Most state Medicaid programs cover GLP-1 receptor agonists with PA criteria that mirror or exceed commercial insurer requirements, though copays are substantially lower. Physicians serving Medicaid-predominant practices should consult each state's preferred drug list (PDL).

A 2022 analysis in Diabetes Care examining 22 commercial formularies found that GLP-1 receptor agonists carried prior authorization requirements on 91% of formularies reviewed, with step therapy required on 68%, reflecting a national pattern consistent with Aetna's approach [22].

Documenting Medical Necessity: A Practical Checklist for Prescribers

Thorough documentation at the point of prescribing reduces back-and-forth with Aetna's pharmacy benefit management and improves first-pass PA approval rates.

The chart note and PA submission should each contain: (1) confirmed type 2 diabetes diagnosis with ICD-10 code; (2) most recent A1C (date, value, lab name); (3) current medications with start dates and doses; (4) metformin trial documentation or written contraindication statement; (5) second-agent trial documentation or contraindication; (6) current eGFR with date; (7) any active ASCVD diagnosis codes; (8) body weight and BMI; and (9) a statement of why the requested drug is the medically appropriate choice for this patient.

The FDA label for Trulicity notes that "clinical studies have demonstrated that GLP-1 receptor agonists, when used in combination with basal insulin or other antidiabetic agents, provide additional glycemic improvement" [2], which supports medical necessity arguments in polypharmacy cases.

A 2023 Endocrine Practice review of GLP-1 PA outcomes found that PA requests accompanied by a structured letter of medical necessity citing guideline-concordant criteria were approved on first submission at a rate of 71% compared with 43% for unstructured submissions [23]. That 28-percentage-point gap underscores that how the request is documented matters as much as whether the patient meets criteria.

The first Aetna PA submission for dulaglutide should include a complete structured letter of medical necessity referencing the ADA 2024 Standards of Care [5], the REWIND cardiovascular outcome data [4], and the current Trulicity FDA label [2] to achieve the highest probability of first-pass approval.